| Urinary Bladder Diseases |
NCT00589017: Tamoxifen in Treating Patients With Metastatic Bladder Cancer That Did Not Respond to Previous Chemotherapy |
|
|
| Recruiting | 2 | 75 | US, Europe | tamoxifen citrate, immunohistochemistry staining method, laboratory biomarker analysis | Baylor College of Medicine | Bladder Cancer | 07/10 | | | |
| Active, not recruiting | 2 | 64 | Europe | Standard planning radiotherapy, Adaptive planning radiotherapy | Institute of Cancer Research, United Kingdom, Cancer Research UK | Bladder Cancer | 07/17 | 01/25 | | |
NCT01956253: Single Subject Neratinib in Bladder Cancer (NRR) |
|
|
| No Longer Available | N/A | | US | Neratinib | UNC Lineberger Comprehensive Cancer Center | Bladder Cancer | 09/13 | 06/14 | | |
NCT02186925: A Prospective Study of Clinical Factors Affecting Disease Progression and Treatment Results of Patients With Tumors of the Prostate, Bladder and Kidney. |
|
|
| Recruiting | N/A | 1000 | RoW | | Meir Medical Center | Kidney Cancer, Prostate Cancer, Bladder Cancer | 08/19 | 08/25 | | |
NCT02315950: The Use of cineMRI to Evaluate Botox in Patients With Medication Refractory Overactive Bladder |
|
|
| Recruiting | N/A | 10 | US | Botulinum toxin and cineMRI-UDS | Cedars-Sinai Medical Center | Overactive Bladder | 12/25 | 12/25 | | |